Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-10

AUTHORS

G. Kong, M. Thompson, M. Collins, A. Herschtal, M. S. Hofman, V. Johnston, P. Eu, M. Michael, Rodney J. Hicks

ABSTRACT

PURPOSE: To review the response and outcomes of (177)Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels of somatostatin receptors with uncontrolled symptoms or disease progression. METHODS: A total of 68 patients (39 men; 17 - 76 years of age) who had completed an induction course of at least three cycles of LuTate PRCRT between January 2006 and June 2010 were reviewed. Ten patients were treated for uncontrolled symptoms and 58 had disease progression despite conventional treatment. The majority had four induction LuTate cycles (median treatment duration 5 months and cumulative activity 31 GBq), and 63 patients had concomitant 5-FU radiosensitizing infusional chemotherapy. Factors predicting overall survival were assessed using the log-rank test and Cox proportional hazards regression. RESULTS: Of those treated for uncontrolled symptoms, 70 % received benefit maintained for at least 6 months after treatment. Among patients with progressive disease 68 % showed stabilization or regression on CT, 67 % on molecular imaging and 56 % biochemically up to 12 months after treatment; 32 patients died. Overall survival rates at 2 and 5 year were 72.1 % and 52.1 %, respectively. Median overall survival was not estimable at a median follow-up of 60 months (range 5 - 86 months). Nonpancreatic primary sites, dominant liver metastases, lesion size <5 cm and the use of 5-FU chemotherapy were statistically significantly associated with objective response. A disseminated pattern and a high disease burden (whole-body retention index) were associated with an increased risk of death. Objective biochemical, molecular imaging and CT responses were all associated with longer overall survival. CONCLUSION: A high proportion of patients with progressive NET or uncontrolled symptoms received therapeutic benefit from LuTate with concomitant 5-FU chemotherapy. The achievement of objective biochemical, molecular or CT responses within 12 months was associated with improved overall survival. Patients with a primary pancreatic site and larger lesions (>5 cm) appeared to have lower objective response rates and may need a more aggressive treatment approach. More... »

PAGES

1831-1844

References to SciGraph publications

  • 2012-02. Lutetium-labelled peptides for therapy of neuroendocrine tumours in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2011-12. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2011-10. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2013-05. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2012-02. Yttrium-labelled peptides for therapy of NET in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2014-02. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2011-02. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2013-12. Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2013-08. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2010-10. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2013-03. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-01. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00259-014-2788-5

    DOI

    http://dx.doi.org/10.1007/s00259-014-2788-5

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1018243354

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/24844348


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adolescent", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chemoradiotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neuroendocrine Tumors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Octreotide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiopharmaceuticals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, Somatostatin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Peter MacCallum Cancer Centre", 
              "id": "https://www.grid.ac/institutes/grid.1055.1", 
              "name": [
                "Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kong", 
            "givenName": "G.", 
            "id": "sg:person.01122451566.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122451566.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Peter MacCallum Cancer Centre", 
              "id": "https://www.grid.ac/institutes/grid.1055.1", 
              "name": [
                "Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Thompson", 
            "givenName": "M.", 
            "id": "sg:person.01234064627.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234064627.04"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Peter MacCallum Cancer Centre", 
              "id": "https://www.grid.ac/institutes/grid.1055.1", 
              "name": [
                "Department of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Collins", 
            "givenName": "M.", 
            "id": "sg:person.0603361705.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603361705.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Peter MacCallum Cancer Centre", 
              "id": "https://www.grid.ac/institutes/grid.1055.1", 
              "name": [
                "Department of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Herschtal", 
            "givenName": "A.", 
            "id": "sg:person.01337552214.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337552214.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Melbourne", 
              "id": "https://www.grid.ac/institutes/grid.1008.9", 
              "name": [
                "Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia", 
                "Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hofman", 
            "givenName": "M. S.", 
            "id": "sg:person.01012460764.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012460764.55"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Peter MacCallum Cancer Centre", 
              "id": "https://www.grid.ac/institutes/grid.1055.1", 
              "name": [
                "Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Johnston", 
            "givenName": "V.", 
            "id": "sg:person.01357450304.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357450304.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Peter MacCallum Cancer Centre", 
              "id": "https://www.grid.ac/institutes/grid.1055.1", 
              "name": [
                "Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Eu", 
            "givenName": "P.", 
            "id": "sg:person.0602670027.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602670027.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Peter MacCallum Cancer Centre", 
              "id": "https://www.grid.ac/institutes/grid.1055.1", 
              "name": [
                "Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia", 
                "Division of Cancer Medicine, Neuroendocrine Tumour Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Michael", 
            "givenName": "M.", 
            "id": "sg:person.0673420201.89", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673420201.89"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Melbourne", 
              "id": "https://www.grid.ac/institutes/grid.1008.9", 
              "name": [
                "Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia", 
                "Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hicks", 
            "givenName": "Rodney J.", 
            "id": "sg:person.01121233254.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121233254.97"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00259-011-2002-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003496649", 
              "https://doi.org/10.1007/s00259-011-2002-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2967/jnumed.111.087932", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004096510"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2967/jnumed.108.057307", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009233958"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-011-1833-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010106448", 
              "https://doi.org/10.1007/s00259-011-1833-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2007.15.2553", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019213889"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-011-1902-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019962478", 
              "https://doi.org/10.1007/s00259-011-1902-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.ejso.2011.08.129", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020693528"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-012-2330-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021999054", 
              "https://doi.org/10.1007/s00259-012-2330-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-012-2330-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021999054", 
              "https://doi.org/10.1007/s00259-012-2330-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2402-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022732322", 
              "https://doi.org/10.1007/s00259-013-2402-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-011-1937-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025979788", 
              "https://doi.org/10.1007/s00259-011-1937-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1053/j.seminoncol.2012.11.006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026389846"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-010-1631-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028002113", 
              "https://doi.org/10.1007/s00259-010-1631-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2504-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028903394", 
              "https://doi.org/10.1007/s00259-013-2504-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/cncr.24796", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028945903"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/cncr.24796", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028945903"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2967/jnumed.109.068957", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028994189"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1102/1470-7330.2005.0006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031348164"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2004.10.016", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032902201"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/cncr.25425", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032996140"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/cncr.25425", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032996140"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.radonc.2011.08.006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033794565"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2547-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035024804", 
              "https://doi.org/10.1007/s00259-013-2547-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2010.33.7873", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036294472"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-011-2039-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043364806", 
              "https://doi.org/10.1007/s00259-011-2039-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2011.37.2151", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044466103"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-012-2055-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048293795", 
              "https://doi.org/10.1007/s00280-012-2055-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1530/erc-10-0282", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049239147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1053/j.seminoncol.2012.11.003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049697739"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-010-1483-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052925405", 
              "https://doi.org/10.1007/s00259-010-1483-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-010-1483-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052925405", 
              "https://doi.org/10.1007/s00259-010-1483-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1089/cbr.2009.0644", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1059242987"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1089/cbr.2012.1276", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1059243283"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1177/030089161009600532", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1078344894"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1177/030089161009600532", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1078344894"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1078601387", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-10", 
        "datePublishedReg": "2014-10-01", 
        "description": "PURPOSE: To review the response and outcomes of (177)Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels of somatostatin receptors with uncontrolled symptoms or disease progression.\nMETHODS: A total of 68 patients (39 men; 17 - 76 years of age) who had completed an induction course of at least three cycles of LuTate PRCRT between January 2006 and June 2010 were reviewed. Ten patients were treated for uncontrolled symptoms and 58 had disease progression despite conventional treatment. The majority had four induction LuTate cycles (median treatment duration 5 months and cumulative activity 31 GBq), and 63 patients had concomitant 5-FU radiosensitizing infusional chemotherapy. Factors predicting overall survival were assessed using the log-rank test and Cox proportional hazards regression.\nRESULTS: Of those treated for uncontrolled symptoms, 70 % received benefit maintained for at least 6 months after treatment. Among patients with progressive disease 68 % showed stabilization or regression on CT, 67 % on molecular imaging and 56 % biochemically up to 12 months after treatment; 32 patients died. Overall survival rates at 2 and 5 year were 72.1 % and 52.1 %, respectively. Median overall survival was not estimable at a median follow-up of 60 months (range 5 - 86 months). Nonpancreatic primary sites, dominant liver metastases, lesion size <5 cm and the use of 5-FU chemotherapy were statistically significantly associated with objective response. A disseminated pattern and a high disease burden (whole-body retention index) were associated with an increased risk of death. Objective biochemical, molecular imaging and CT responses were all associated with longer overall survival.\nCONCLUSION: A high proportion of patients with progressive NET or uncontrolled symptoms received therapeutic benefit from LuTate with concomitant 5-FU chemotherapy. The achievement of objective biochemical, molecular or CT responses within 12 months was associated with improved overall survival. Patients with a primary pancreatic site and larger lesions (>5 cm) appeared to have lower objective response rates and may need a more aggressive treatment approach.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s00259-014-2788-5", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1297401", 
            "issn": [
              "1619-7070", 
              "1619-7089"
            ], 
            "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "10", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "41"
          }
        ], 
        "name": "Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)", 
        "pagination": "1831-1844", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "56ec39bf953bbffaf741848d33d02cfc97894ad5ee116a677ddcf880422543f7"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "24844348"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "101140988"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00259-014-2788-5"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1018243354"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00259-014-2788-5", 
          "https://app.dimensions.ai/details/publication/pub.1018243354"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T09:59", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89814_00000000.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007%2Fs00259-014-2788-5"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2788-5'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2788-5'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2788-5'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2788-5'


     

    This table displays all metadata directly associated to this object as RDF triples.

    296 TRIPLES      21 PREDICATES      75 URIs      36 LITERALS      24 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00259-014-2788-5 schema:about N03dc56b540ce4460b2c8f62fd6b3e995
    2 N1a7f16067093457da216785ba0adbaa8
    3 N296df8e941d540a882a728687430782f
    4 N361216d8dca247beb024df82deeb4392
    5 N3daea617322149a88d4043a2ec4d6cf6
    6 N6eae9f5905d84370b841bcab49580b41
    7 N7f54ee9988ac41f29d21d5cf283f39c7
    8 N8111d72b39584b20b7e056f8af9c57c2
    9 N81d96b2e48bf4541ad7f68d46201b392
    10 Nc48d700054a94eafb4ca67523d7bc1a1
    11 Ncdfa667a18d749529c3b2a7bc2bc494d
    12 Nd3a2dff29ac74310906c537f3d629b7d
    13 Nd72b54890af2446cbc21bceb35b7fd1a
    14 Nd8f88f19600543eeaaef40ed8cc9f820
    15 Ne6245a295dcb4063ad0156620e3e1862
    16 anzsrc-for:11
    17 anzsrc-for:1112
    18 schema:author N3d55baff731946b3b48162dc39b5cf99
    19 schema:citation sg:pub.10.1007/s00259-010-1483-4
    20 sg:pub.10.1007/s00259-010-1631-x
    21 sg:pub.10.1007/s00259-011-1833-x
    22 sg:pub.10.1007/s00259-011-1902-1
    23 sg:pub.10.1007/s00259-011-1937-3
    24 sg:pub.10.1007/s00259-011-2002-y
    25 sg:pub.10.1007/s00259-011-2039-y
    26 sg:pub.10.1007/s00259-012-2330-6
    27 sg:pub.10.1007/s00259-013-2402-2
    28 sg:pub.10.1007/s00259-013-2504-x
    29 sg:pub.10.1007/s00259-013-2547-z
    30 sg:pub.10.1007/s00280-012-2055-z
    31 https://app.dimensions.ai/details/publication/pub.1078601387
    32 https://doi.org/10.1002/cncr.24796
    33 https://doi.org/10.1002/cncr.25425
    34 https://doi.org/10.1016/j.ejso.2011.08.129
    35 https://doi.org/10.1016/j.radonc.2011.08.006
    36 https://doi.org/10.1053/j.seminoncol.2012.11.003
    37 https://doi.org/10.1053/j.seminoncol.2012.11.006
    38 https://doi.org/10.1089/cbr.2009.0644
    39 https://doi.org/10.1089/cbr.2012.1276
    40 https://doi.org/10.1102/1470-7330.2005.0006
    41 https://doi.org/10.1177/030089161009600532
    42 https://doi.org/10.1200/jco.2004.10.016
    43 https://doi.org/10.1200/jco.2007.15.2553
    44 https://doi.org/10.1200/jco.2010.33.7873
    45 https://doi.org/10.1200/jco.2011.37.2151
    46 https://doi.org/10.1530/erc-10-0282
    47 https://doi.org/10.2967/jnumed.108.057307
    48 https://doi.org/10.2967/jnumed.109.068957
    49 https://doi.org/10.2967/jnumed.111.087932
    50 schema:datePublished 2014-10
    51 schema:datePublishedReg 2014-10-01
    52 schema:description PURPOSE: To review the response and outcomes of (177)Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels of somatostatin receptors with uncontrolled symptoms or disease progression. METHODS: A total of 68 patients (39 men; 17 - 76 years of age) who had completed an induction course of at least three cycles of LuTate PRCRT between January 2006 and June 2010 were reviewed. Ten patients were treated for uncontrolled symptoms and 58 had disease progression despite conventional treatment. The majority had four induction LuTate cycles (median treatment duration 5 months and cumulative activity 31 GBq), and 63 patients had concomitant 5-FU radiosensitizing infusional chemotherapy. Factors predicting overall survival were assessed using the log-rank test and Cox proportional hazards regression. RESULTS: Of those treated for uncontrolled symptoms, 70 % received benefit maintained for at least 6 months after treatment. Among patients with progressive disease 68 % showed stabilization or regression on CT, 67 % on molecular imaging and 56 % biochemically up to 12 months after treatment; 32 patients died. Overall survival rates at 2 and 5 year were 72.1 % and 52.1 %, respectively. Median overall survival was not estimable at a median follow-up of 60 months (range 5 - 86 months). Nonpancreatic primary sites, dominant liver metastases, lesion size <5 cm and the use of 5-FU chemotherapy were statistically significantly associated with objective response. A disseminated pattern and a high disease burden (whole-body retention index) were associated with an increased risk of death. Objective biochemical, molecular imaging and CT responses were all associated with longer overall survival. CONCLUSION: A high proportion of patients with progressive NET or uncontrolled symptoms received therapeutic benefit from LuTate with concomitant 5-FU chemotherapy. The achievement of objective biochemical, molecular or CT responses within 12 months was associated with improved overall survival. Patients with a primary pancreatic site and larger lesions (>5 cm) appeared to have lower objective response rates and may need a more aggressive treatment approach.
    53 schema:genre research_article
    54 schema:inLanguage en
    55 schema:isAccessibleForFree true
    56 schema:isPartOf N329b6b0554b849babd5156e71768a57c
    57 N5075c35ac8fa40d9b9c24f3b6ec3395d
    58 sg:journal.1297401
    59 schema:name Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
    60 schema:pagination 1831-1844
    61 schema:productId N07f1d61d86fd443b9af8658ca11d8051
    62 N593652171ea8446290fe291fa31de30c
    63 N72ae1541f8554c4db3078e1dd703b42e
    64 Nce6a6f0fdfd645c3a6eb3297ad9ce0b8
    65 Nf5ab62240cf0414fa5c6a985f68e0099
    66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018243354
    67 https://doi.org/10.1007/s00259-014-2788-5
    68 schema:sdDatePublished 2019-04-11T09:59
    69 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    70 schema:sdPublisher N7294ec9b5b054fdc86cf3f11614bcc8d
    71 schema:url http://link.springer.com/10.1007%2Fs00259-014-2788-5
    72 sgo:license sg:explorer/license/
    73 sgo:sdDataset articles
    74 rdf:type schema:ScholarlyArticle
    75 N006ed7484a3d433a9669cb7ee5603e97 rdf:first sg:person.0603361705.13
    76 rdf:rest N59d1b2d3ca044c99a7b6b99f9af2631c
    77 N03dc56b540ce4460b2c8f62fd6b3e995 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    78 schema:name Middle Aged
    79 rdf:type schema:DefinedTerm
    80 N07f1d61d86fd443b9af8658ca11d8051 schema:name dimensions_id
    81 schema:value pub.1018243354
    82 rdf:type schema:PropertyValue
    83 N0d052803d1b9483e9c98ce8033151e9e rdf:first sg:person.0673420201.89
    84 rdf:rest N1143ad9a2f674596bea3a058984c1279
    85 N1143ad9a2f674596bea3a058984c1279 rdf:first sg:person.01121233254.97
    86 rdf:rest rdf:nil
    87 N1a7f16067093457da216785ba0adbaa8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    88 schema:name Receptors, Somatostatin
    89 rdf:type schema:DefinedTerm
    90 N296df8e941d540a882a728687430782f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    91 schema:name Aged
    92 rdf:type schema:DefinedTerm
    93 N329b6b0554b849babd5156e71768a57c schema:issueNumber 10
    94 rdf:type schema:PublicationIssue
    95 N361216d8dca247beb024df82deeb4392 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    96 schema:name Adolescent
    97 rdf:type schema:DefinedTerm
    98 N3d55baff731946b3b48162dc39b5cf99 rdf:first sg:person.01122451566.24
    99 rdf:rest N9b4bdd35f34a43d6a6e124a65a856eea
    100 N3daea617322149a88d4043a2ec4d6cf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    101 schema:name Adult
    102 rdf:type schema:DefinedTerm
    103 N5075c35ac8fa40d9b9c24f3b6ec3395d schema:volumeNumber 41
    104 rdf:type schema:PublicationVolume
    105 N593652171ea8446290fe291fa31de30c schema:name pubmed_id
    106 schema:value 24844348
    107 rdf:type schema:PropertyValue
    108 N59d1b2d3ca044c99a7b6b99f9af2631c rdf:first sg:person.01337552214.34
    109 rdf:rest Nc49f9b5a503e40dc8dd95930f225acf7
    110 N6eae9f5905d84370b841bcab49580b41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Humans
    112 rdf:type schema:DefinedTerm
    113 N7294ec9b5b054fdc86cf3f11614bcc8d schema:name Springer Nature - SN SciGraph project
    114 rdf:type schema:Organization
    115 N72ae1541f8554c4db3078e1dd703b42e schema:name doi
    116 schema:value 10.1007/s00259-014-2788-5
    117 rdf:type schema:PropertyValue
    118 N7f54ee9988ac41f29d21d5cf283f39c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Chemoradiotherapy
    120 rdf:type schema:DefinedTerm
    121 N8111d72b39584b20b7e056f8af9c57c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Male
    123 rdf:type schema:DefinedTerm
    124 N81d96b2e48bf4541ad7f68d46201b392 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Female
    126 rdf:type schema:DefinedTerm
    127 N9b4bdd35f34a43d6a6e124a65a856eea rdf:first sg:person.01234064627.04
    128 rdf:rest N006ed7484a3d433a9669cb7ee5603e97
    129 Nb3b4d02fd5344445a74fd913c724c815 rdf:first sg:person.01357450304.44
    130 rdf:rest Nf6bf9a322e3040a28da35fd9acdff73f
    131 Nc48d700054a94eafb4ca67523d7bc1a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Antineoplastic Agents
    133 rdf:type schema:DefinedTerm
    134 Nc49f9b5a503e40dc8dd95930f225acf7 rdf:first sg:person.01012460764.55
    135 rdf:rest Nb3b4d02fd5344445a74fd913c724c815
    136 Ncdfa667a18d749529c3b2a7bc2bc494d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Survival Analysis
    138 rdf:type schema:DefinedTerm
    139 Nce6a6f0fdfd645c3a6eb3297ad9ce0b8 schema:name readcube_id
    140 schema:value 56ec39bf953bbffaf741848d33d02cfc97894ad5ee116a677ddcf880422543f7
    141 rdf:type schema:PropertyValue
    142 Nd3a2dff29ac74310906c537f3d629b7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Neuroendocrine Tumors
    144 rdf:type schema:DefinedTerm
    145 Nd72b54890af2446cbc21bceb35b7fd1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Treatment Outcome
    147 rdf:type schema:DefinedTerm
    148 Nd8f88f19600543eeaaef40ed8cc9f820 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name Octreotide
    150 rdf:type schema:DefinedTerm
    151 Ne6245a295dcb4063ad0156620e3e1862 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name Radiopharmaceuticals
    153 rdf:type schema:DefinedTerm
    154 Nf5ab62240cf0414fa5c6a985f68e0099 schema:name nlm_unique_id
    155 schema:value 101140988
    156 rdf:type schema:PropertyValue
    157 Nf6bf9a322e3040a28da35fd9acdff73f rdf:first sg:person.0602670027.22
    158 rdf:rest N0d052803d1b9483e9c98ce8033151e9e
    159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    160 schema:name Medical and Health Sciences
    161 rdf:type schema:DefinedTerm
    162 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    163 schema:name Oncology and Carcinogenesis
    164 rdf:type schema:DefinedTerm
    165 sg:journal.1297401 schema:issn 1619-7070
    166 1619-7089
    167 schema:name European Journal of Nuclear Medicine and Molecular Imaging
    168 rdf:type schema:Periodical
    169 sg:person.01012460764.55 schema:affiliation https://www.grid.ac/institutes/grid.1008.9
    170 schema:familyName Hofman
    171 schema:givenName M. S.
    172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012460764.55
    173 rdf:type schema:Person
    174 sg:person.01121233254.97 schema:affiliation https://www.grid.ac/institutes/grid.1008.9
    175 schema:familyName Hicks
    176 schema:givenName Rodney J.
    177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121233254.97
    178 rdf:type schema:Person
    179 sg:person.01122451566.24 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
    180 schema:familyName Kong
    181 schema:givenName G.
    182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122451566.24
    183 rdf:type schema:Person
    184 sg:person.01234064627.04 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
    185 schema:familyName Thompson
    186 schema:givenName M.
    187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234064627.04
    188 rdf:type schema:Person
    189 sg:person.01337552214.34 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
    190 schema:familyName Herschtal
    191 schema:givenName A.
    192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337552214.34
    193 rdf:type schema:Person
    194 sg:person.01357450304.44 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
    195 schema:familyName Johnston
    196 schema:givenName V.
    197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357450304.44
    198 rdf:type schema:Person
    199 sg:person.0602670027.22 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
    200 schema:familyName Eu
    201 schema:givenName P.
    202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602670027.22
    203 rdf:type schema:Person
    204 sg:person.0603361705.13 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
    205 schema:familyName Collins
    206 schema:givenName M.
    207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603361705.13
    208 rdf:type schema:Person
    209 sg:person.0673420201.89 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
    210 schema:familyName Michael
    211 schema:givenName M.
    212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673420201.89
    213 rdf:type schema:Person
    214 sg:pub.10.1007/s00259-010-1483-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052925405
    215 https://doi.org/10.1007/s00259-010-1483-4
    216 rdf:type schema:CreativeWork
    217 sg:pub.10.1007/s00259-010-1631-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028002113
    218 https://doi.org/10.1007/s00259-010-1631-x
    219 rdf:type schema:CreativeWork
    220 sg:pub.10.1007/s00259-011-1833-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010106448
    221 https://doi.org/10.1007/s00259-011-1833-x
    222 rdf:type schema:CreativeWork
    223 sg:pub.10.1007/s00259-011-1902-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019962478
    224 https://doi.org/10.1007/s00259-011-1902-1
    225 rdf:type schema:CreativeWork
    226 sg:pub.10.1007/s00259-011-1937-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025979788
    227 https://doi.org/10.1007/s00259-011-1937-3
    228 rdf:type schema:CreativeWork
    229 sg:pub.10.1007/s00259-011-2002-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1003496649
    230 https://doi.org/10.1007/s00259-011-2002-y
    231 rdf:type schema:CreativeWork
    232 sg:pub.10.1007/s00259-011-2039-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1043364806
    233 https://doi.org/10.1007/s00259-011-2039-y
    234 rdf:type schema:CreativeWork
    235 sg:pub.10.1007/s00259-012-2330-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021999054
    236 https://doi.org/10.1007/s00259-012-2330-6
    237 rdf:type schema:CreativeWork
    238 sg:pub.10.1007/s00259-013-2402-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022732322
    239 https://doi.org/10.1007/s00259-013-2402-2
    240 rdf:type schema:CreativeWork
    241 sg:pub.10.1007/s00259-013-2504-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028903394
    242 https://doi.org/10.1007/s00259-013-2504-x
    243 rdf:type schema:CreativeWork
    244 sg:pub.10.1007/s00259-013-2547-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1035024804
    245 https://doi.org/10.1007/s00259-013-2547-z
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1007/s00280-012-2055-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1048293795
    248 https://doi.org/10.1007/s00280-012-2055-z
    249 rdf:type schema:CreativeWork
    250 https://app.dimensions.ai/details/publication/pub.1078601387 schema:CreativeWork
    251 https://doi.org/10.1002/cncr.24796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028945903
    252 rdf:type schema:CreativeWork
    253 https://doi.org/10.1002/cncr.25425 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032996140
    254 rdf:type schema:CreativeWork
    255 https://doi.org/10.1016/j.ejso.2011.08.129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020693528
    256 rdf:type schema:CreativeWork
    257 https://doi.org/10.1016/j.radonc.2011.08.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033794565
    258 rdf:type schema:CreativeWork
    259 https://doi.org/10.1053/j.seminoncol.2012.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049697739
    260 rdf:type schema:CreativeWork
    261 https://doi.org/10.1053/j.seminoncol.2012.11.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026389846
    262 rdf:type schema:CreativeWork
    263 https://doi.org/10.1089/cbr.2009.0644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059242987
    264 rdf:type schema:CreativeWork
    265 https://doi.org/10.1089/cbr.2012.1276 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059243283
    266 rdf:type schema:CreativeWork
    267 https://doi.org/10.1102/1470-7330.2005.0006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031348164
    268 rdf:type schema:CreativeWork
    269 https://doi.org/10.1177/030089161009600532 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078344894
    270 rdf:type schema:CreativeWork
    271 https://doi.org/10.1200/jco.2004.10.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032902201
    272 rdf:type schema:CreativeWork
    273 https://doi.org/10.1200/jco.2007.15.2553 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019213889
    274 rdf:type schema:CreativeWork
    275 https://doi.org/10.1200/jco.2010.33.7873 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036294472
    276 rdf:type schema:CreativeWork
    277 https://doi.org/10.1200/jco.2011.37.2151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044466103
    278 rdf:type schema:CreativeWork
    279 https://doi.org/10.1530/erc-10-0282 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049239147
    280 rdf:type schema:CreativeWork
    281 https://doi.org/10.2967/jnumed.108.057307 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009233958
    282 rdf:type schema:CreativeWork
    283 https://doi.org/10.2967/jnumed.109.068957 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028994189
    284 rdf:type schema:CreativeWork
    285 https://doi.org/10.2967/jnumed.111.087932 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004096510
    286 rdf:type schema:CreativeWork
    287 https://www.grid.ac/institutes/grid.1008.9 schema:alternateName University of Melbourne
    288 schema:name Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrew’s Place, 3002, East Melbourne, VIC, Australia
    289 Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia
    290 rdf:type schema:Organization
    291 https://www.grid.ac/institutes/grid.1055.1 schema:alternateName Peter MacCallum Cancer Centre
    292 schema:name Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrew’s Place, 3002, East Melbourne, VIC, Australia
    293 Department of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
    294 Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia
    295 Division of Cancer Medicine, Neuroendocrine Tumour Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
    296 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...